Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer
The Claudin 18.2 (CLDN18.2)-targeted IgG1 monoclonal antibody zolbetuximab (Vyloy) in combination with frontline chemotherapy extended progression-free survival (PFS) and overall survival (OS) vs placebo plus chemotherapy in patients with HER2-negative, …